Please login to the form below

Not currently logged in
Email:
Password:

cardiovascular disease

This page shows the latest cardiovascular disease news and features for those working in and with pharma, biotech and healthcare.

J&J says real-world data finds no amputation risk for Invokana

J&J says real-world data finds no amputation risk for Invokana

There was also no difference between the groups in a subset of patients with established cardiovascular disease. ... AZ is still waiting for data read-outs from its cardiovascular outcomes study (due in 2019), but presented real-world evidence for a

Latest news

  • Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use? Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use?

    Amgen’s Repatha has just been granted EU approval to treat adults with established atherosclerotic cardiovascular disease, an important step towards broadening its uptake. ... treatment with Roche's top-selling Herceptin can be cut from 12 months to

  • Esperion craters as deaths mar atherosclerosis drug study Esperion craters as deaths mar atherosclerosis drug study

    disease (ASCVD) who were not able to control their cholesterol levels using statins alone. ... The efficacy results - which also included a significant reduction in a marker of underlying inflammation associated with cardiovascular disease called

  • Disruptive technologies set to stabilise soaring drug prices Disruptive technologies set to stabilise soaring drug prices

    With the new technology, researchers are hoping to “generate more accurate hypotheses faster, making the drug discovery process less expensive and more effective”, said Valentina Gburcik, GlobalData’s cardiovascular and metabolic ... targets for a

  • AZ taps Ionis for another drug, this time in NASH AZ taps Ionis for another drug, this time in NASH

    It’s the third time AZ has taken up an option on an Ionis drug under a 2015 alliance in the area of cardiovascular, metabolic and kidney disease, after earlier deals ... for cardiovascular drug AZD8233 and kidney disease candidate AZD2373.

  • Segmentation, evolved Segmentation, evolved

    Elias Zerhouni, Sanofi’s Global R&D head, pointed to Sanofi’s thinking when he said: “Not all patients with heart disease are the same. ... The data demonstrates that a precision-medicine approach in the field of cardiovascular disease may further

More from news
Approximately 16 fully matching, plus 245 partially matching documents found.

Latest Intelligence

  • The threat of antimicrobial resistance The threat of antimicrobial resistance

    the low commercial value placed on antibiotic drugs compared to more lucrative sectors such as cardiovascular disease and cancer. ... By January 2018, the US Centers for Disease Control and Prevention had reported 29 cases of MCR resistance identified

  • Pharma deals continue to slide Pharma deals continue to slide

    Cerecor has sold its kappa opioid receptor antagonist in phase 2 to Janssen (J&J) and Xoma has licensed its interleukin 1 beta intellectual property for cardiovascular disease to Novartis plus ... Gevokizumab plus IP for use of IL-1 beta targeting

  • Perfecting the pharmaceutical pipeline with AI Perfecting the pharmaceutical pipeline with AI

    This has a knock-on effect for research around rare disease types specifically. ... For example, a drug being used for cardiovascular disease might be found to have useful qualities for neurological diseases.

  • The EarthWorks: New ways to improve patient care The EarthWorks: New ways to improve patient care

    Keeping people well and preventing illness. Technology is only interesting socially when it is boring technologically; we have to have scale to begin to prevent disease on a population level. ... cardiovascular disease and transplantation.

  • Deal Watch March 2016 Deal Watch March 2016

    Padlock's technology targets autoimmune disorders with protein/peptidyl arginine deiminase (PAD) inhibitors and offers the potential to prevent disease development in patients with early stage disease. ... Co-development. $130. Lipigon/ AstraZeneca.

More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.

Latest appointments

  • Sanifit appoints Alexander Gold chief medical officer Sanifit appoints Alexander Gold chief medical officer

    Alex arrives here with first class operational and clinical development expertise in novel drug therapies, targeting cardiovascular and metabolic disease and kidney disease amongst others.

  • Leading Edge bolsters its delivery team Leading Edge bolsters its delivery team

    Francesca Worthington joins the group as an account manager after working across a variety of medical communication programmes and in a number of therapy areas, including haematology, ophthalmology, cardiovascular disease and

  • MyoKardia appoints COO and medical affairs VP MyoKardia appoints COO and medical affairs VP

    Prior to this, Dr Lee was therapeutic area head for cardiovascular, metabolic, respiratory and infectious disease programmes at Genentech. ... Their expertise and counsel will broaden our base of leadership and support our mission to change the world for

  • The Medicines Company appoints Biogen's Tony Kingsley The Medicines Company appoints Biogen's Tony Kingsley

    He will also serve at the company, which focuses on serious infectious disease care, acute cardiovascular care, and surgery and perioperative care, as its president, taking over from Glenn Sblendorio, who

  • MedImmune appoints Dr Christopher Rhodes MedImmune appoints Dr Christopher Rhodes

    AstraZeneca's biologics research and development arm MedImmune has appointed Dr Christopher Rhodes as vice president, cardiovascular and metabolic disease (CVMD) research. ... exciting time for our Cardiovascular and Metabolic Disease therapeutic area.

More from appointments
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics